NCT00482053 2018-05-14
Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
Stanford University
Phase 2 Terminated
Stanford University
Children's Oncology Group
Memorial Sloan Kettering Cancer Center
Barbara Ann Karmanos Cancer Institute